Crenolanib
- Generic Name
- Crenolanib
- Drug Type
- Small Molecule
- Chemical Formula
- C26H29N5O2
- CAS Number
- 670220-88-9
- Unique Ingredient Identifier
- LQF7I567TQ
- Background
Crenolanib is under investigation for the treatment of Diffuse Intrinsic Pontine Glioma and Progressive or Refractory High-Grade Glioma.
Study of Crenolanib in Combination With Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia and Activating FLT3 Mutations
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Drug: chemotherapy (Mitoxantrone, Cytarabine)Drug: PlaceboOther: Allogeneic stem cell transplantation
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2021-10-06
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 9
- Registration Number
- NCT02298166
- Locations
- 🇩🇪
Ulm University Hospital, Ulm, Germany
A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
- Conditions
- Newly Diagnosed AML With FLT3 Activating Mutations
- Interventions
- First Posted Date
- 2014-11-05
- Last Posted Date
- 2024-02-02
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 44
- Registration Number
- NCT02283177
- Locations
- 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸Roswell Park Cancer Institute, Buffalo, New York, United States
Crenolanib in Combination With Sorafenib in Patients With Refractory or Relapsed Hematologic Malignancies
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2014-10-21
- Last Posted Date
- 2017-10-03
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT02270788
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations
- Conditions
- Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies
- Interventions
- First Posted Date
- 2012-08-06
- Last Posted Date
- 2023-11-30
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 56
- Registration Number
- NCT01657682
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations
- Conditions
- Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
- Interventions
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT01522469
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
PDGFR Inhibitor Crenolanib in Children/Young Adults With Diffuse Intrinsic Pontine Glioma or Recurrent High-Grade Glioma
- Conditions
- Diffuse Intrinsic Pontine GliomaProgressive or Refractory High-Grade Glioma
- Interventions
- First Posted Date
- 2011-07-13
- Last Posted Date
- 2017-04-26
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 55
- Registration Number
- NCT01393912
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene
- Conditions
- D842-related Mutant GIST
- First Posted Date
- 2010-11-18
- Last Posted Date
- 2018-06-28
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01243346
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸Knight Cancer Institute, Oregon Health and Science University, Portland, Oregon, United States
Study of Crenolanib, a Selective and Potent Inhibitor of PDGFR, for the Treatment of Adult Gliomas
- First Posted Date
- 2010-10-28
- Last Posted Date
- 2018-07-05
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT01229644
- Locations
- 🇺🇸
Harold Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas, United States
CP-868,596 And CP-868,596 Plus AG-013736 In Combination With Docetaxel In Advanced Solid Tumors
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2009-07-30
- Last Posted Date
- 2012-01-19
- Lead Sponsor
- Arog Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00949624
- Locations
- 🇦🇺
Pfizer Investigational Site, East Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.